Library classification

ROC.ai Expands into New Markets with Launch of Iris Recognition, Driving American-Made Innovation in Multimodal Biometrics

Retrieved on:

Monday, December 4, 2023

DENVER, Dec. 4, 2023 /PRNewswire/ -- Continuing their blockbuster drive to put American-made computer vision algorithms at the top of global performance, Rank One Computing (ROC.ai) has announced the launch of their groundbreaking iris recognition solution. By leveraging their cutting-edge AI, ML, and deep learning expertise, ROC.ai was able to develop an iris matching algorithm that outperforms global competitors in just a few short months.

Key Points:

We announced our first fingerprint matching algorithms earlier this year and now we have one of the leading iris algorithms.
We're developing from the ground up, here in the U.S., and competing head-to-head with established foreign biometric giants," said ROC.ai CEO Scott Swann.
Iris recognition, a form of biometric authentication that relies on the unique patterns in a person's iris, has been gaining traction for its high accuracy and security.
"The ROC team's journey began less than six months ago with a commitment to revolutionize the field of iris recognition.

Cytokinetics Reports Second Quarter 2023 Financial Results

Retrieved on:

Thursday, August 3, 2023

SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the second quarter of 2023. Net loss for the second quarter was $128.6 million, or $1.34 per share, compared to net loss for the second quarter of 2022 of $19.8 million, or $0.23 per share. Cash, cash equivalents and investments totaled $592.6 million at June 30, 2023.

Key Points:

Completed Enrollment in SEQUOIA-HCM, Pivotal Phase 3 Trial of Aficamten in Obstructive HCM; On Track for Topline Results by the End of the Year
ACACIA-HCM, a Pivotal Phase 3 Clinical Trial of Aficamten in Non-Obstructive HCM, Expected to Start in September 2023
SOUTH SAN FRANCISCO, Calif., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the second quarter of 2023.
Net loss for the second quarter was $128.6 million, or $1.34 per share, compared to net loss for the second quarter of 2022 of $19.8 million, or $0.23 per share.
Cash, cash equivalents and investments totaled $592.6 million at June 30, 2023.
We are pleased with ongoing study conduct and expect topline results from SEQUOIA-HCM by year end,” said Robert I. Blum, Cytokinetics’ President and Chief Executive Officer.

Everbridge Partners With International Telecommunications Union (ITU) to Contribute Private Sector Expertise to Early Warnings For All Initiative

Retrieved on:

Tuesday, June 6, 2023

View the full release here: https://www.businesswire.com/news/home/20230606005560/en/

Key Points:

View the full release here: https://www.businesswire.com/news/home/20230606005560/en/
Everbridge Partners with International Telecommunications Union (ITU) to Contribute Private Sector Expertise to Early Warnings For All Initiative (Photo: Business Wire)
As an Industry Sector Member to the ITU Development Sector led by Comas Zavazava, Everbridge will advocate for and collaborate on cell-broadcast public warning technology as the most effective means to reach citizens in an emergency – the last-mile of the early warning process.
“We applaud the work of the ITU in building an ecosystem of providers committed to delivering on the vision of Early Warnings for All,” said David Wagner, CEO of Everbridge.
The effort is focused on ensuring that by 2027, every person on Earth is protected by an early warning system.
Its main concept was published in the ITU blog on Early warning systems: Saving Lives through mobile connection .

Cytokinetics Presents New Data From REDWOOD-HCM OLE in Late Breaking Clinical Trial Session at the HFSA Annual Scientific Meeting

Retrieved on:

Sunday, October 2, 2022

SD, Heart Failure Society of America, Health status of Asian Americans, Week, Cytokinetics, Library classification, Heart failure, Patient, Clinical study design, Quality of life, SAN, NYHA, New York Heart Association Functional Classification, KCCQ, GLOBE, OLE, Pharmaceutical industry

SOUTH SAN FRANCISCO, Calif., Oct. 02, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced new data on symptom improvement and quality of life related to treatment with aficamten in REDWOOD-HCM OLE (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM Open Label Extension) in a Late Breaking Clinical Trials session at the Heart Failure Society of America (HFSA) Annual Scientific Meeting in Washington, D.C.

Key Points:

As early as Week 12, patients experienced substantial and significant symptom improvements as measured by the change in their KCCQ scores.
As REDWOOD-HCM OLE continues, aficamten is also under study in SEQUOIA-HCM, the Phase 3 registrational clinical trial in patients with obstructive HCM.
For further information regarding these and other risks related to Cytokinetics' business, investors should consult Cytokinetics' filings with the Securities and Exchange Commission.
CYTOKINETICS and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Cytokinetics Reports Second Quarter 2022 Financial Results

Retrieved on:

Thursday, August 4, 2022

SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the second quarter of 2022. Net loss for the second quarter was $19.8 million, or $0.23 per share, compared to net loss for the second quarter of 2021 of $61.6 million, or $0.86 per share. Cash, cash equivalents and investments totaled $596.7 million at June 30, 2022.

Key Points:

Advisory Committee Meeting to Review NDA for Omecamtiv Mecarbil Scheduled for December 13, 2022; PDUFA Target Action Date Set for February 28, 2023
Company Revises 2022 Financial Guidance; Reduces Projected Spending for 2022
SOUTH SAN FRANCISCO, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported financial results for the second quarter of 2022.
Net loss for the second quarter was $19.8 million, or $0.23 per share, compared to net loss for the second quarter of 2021 of $61.6 million, or $0.86 per share.
During the second quarter we made progress across regulatory, clinical and financial objectives.
CYTOKINETICS and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Cytokinetics Announces Data From REDWOOD-HCM OLE and GALACTIC-HF Presented as Late Breaking Science Presentations at the European Society of Cardiology Heart Failure 2022 Congress

Retrieved on:

Monday, May 23, 2022

SOUTH SAN FRANCISCO, Calif., May 23, 2022 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced positive data relating to aficamten from REDWOOD-HCM OLE (Randomized Evaluation of Dosing With CK-274 in Obstructive Outflow Disease in HCM Open Label Extension) and the results from two additional analyses of omecamtiv mecarbil from GALACTIC-HF (Global Approach to Lowering Adverse Cardiac Outcomes Through Improving Contractility in Heart Failure), all presented in Late-Breaking Science Sessions at Heart Failure 2022, an International Congress of the European Society of Cardiology. The analysis from GALACTIC-HF related to low blood pressure has been simultaneously published in the European Heart Journal.

Key Points:

The analysis from GALACTIC-HF related to low blood pressure has been simultaneously published in the European Heart Journal.
These findings add to the growing body of evidence demonstrating that patients with clinical features suggestive of high-risk heart failure respond favorably to omecamtiv mecarbil.
Ahmad Masri, M.D., Assistant Professor of Medicine, Division of Cardiovascular Medicine, School of Medicine, Oregon Health & Science University, presented the first long-term data from REDWOOD-HCM OLE.
Patients enrolled in REDWOOD-HCM OLE have completed participation in REDWOOD-HCM, the Phase 2 clinical trial of aficamten.

Hitachi to Establish Hitachi Automation to Reinforce Robotic SI Business in Japan and ASEAN Countries

Retrieved on:

Thursday, January 27, 2022

TOKYO, Jan 27, 2022 - (JCN Newswire) - Hitachi, Ltd. (TSE: 6501, "Hitachi") and Hitachi Industrial Equipment Systems Co., Ltd. ("Hitachi Industrial Equipment Systems") today announced that they have been accelerating the global development of the line building business leveraging industrial robots ("the robotic SI(1) business") and will establish Hitachi Automation, Ltd. ("Hitachi Automation") on April 1, 2022, by reorganizing and integrating the operations and resources within group companies, with the aim of reinforcing the robotic SI business in Japan and ASEAN countries.

Key Points:

TOKYO, Jan 27, 2022 - (JCN Newswire) - Hitachi, Ltd. (TSE: 6501, "Hitachi") and Hitachi Industrial Equipment Systems Co., Ltd. ("Hitachi Industrial Equipment Systems") today announced that they have been accelerating the global development of the line building business leveraging industrial robots ("the robotic SI(1) business") and will establish Hitachi Automation, Ltd. ("Hitachi Automation") on April 1, 2022, by reorganizing and integrating the operations and resources within group companies, with the aim of reinforcing the robotic SI business in Japan and ASEAN countries.
Moreover, the Hitachi Group aims to be a global leader in the robotic SI business based on JR Automation which is developing business mainly in North America and Europe, Hitachi Automation and Kyoto Robotics which will be developing business in Japan and ASEAN countries.
With the goal of increasing its competitiveness in the robotic SI business in Japan and ASEAN countries, Hitachi has decided to integrate its robotic SI business resources into Hitachi Automation.
Hitachi Industrial Equipment Systems develops the robotic SI business centering on assembly and conveyor processes in a wide range of business categories leveraging its control technologies, such as connected products.

Arbor Digital and Digital Asset Research Announce Partnership to Enhance Crypto Asset Selection Due Diligence

Retrieved on:

Thursday, January 20, 2022

ANCHORAGE, Alaska, Jan. 20, 2022 /PRNewswire/ -- Arbor Digital is partnering with Digital Asset Research (DAR)to enhance their crypto asset due diligence process which powers their SMA offer.

Key Points:

ANCHORAGE, Alaska, Jan. 20, 2022 /PRNewswire/ -- Arbor Digital is partnering with Digital Asset Research (DAR)to enhance their crypto asset due diligence process which powers their SMA offer.
Digital Asset Research is a specialist provider of crypto data and research.
When asked about the partnership, Doug Schwenk, CEO of DAR said, "We're excited to partner with Arbor, a leader in digital asset solutions for RIAs.
The institutional rigor Arbor applies to digital asset markets is important to further adoption and is aligned with DAR's philosophy.

DAR Announces January 2022 Crypto Exchange and Asset Vetting Results

Retrieved on:

Thursday, January 20, 2022

NEW YORK, Jan. 20, 2022 /PRNewswire-PRWeb/ -- Digital Asset Research (DAR) , a leading provider of crypto asset data and research, today announced the release of its January 2022 Crypto Exchange Vetting and Asset Vetting results.

Key Points:

NEW YORK, Jan. 20, 2022 /PRNewswire-PRWeb/ -- Digital Asset Research (DAR) , a leading provider of crypto asset data and research, today announced the release of its January 2022 Crypto Exchange Vetting and Asset Vetting results.
The Asset Vetting process evaluated over 1000 digital assets to identify 48 benchmark assets and over 600 non-benchmark assets.
The results of the Exchange Vetting and Asset Vetting processes are used by DAR clients to determine accurate asset prices and to identify safe venues in the market.
Digital Asset Research (DAR) is a specialist provider of crypto data and research.

DAR Announces Enhanced Crypto Asset Vetting Reports for Institutional Clients

Retrieved on:

Thursday, November 18, 2021

NEW YORK, Nov. 18, 2021 /PRNewswire-PRWeb/ -- Digital Asset Research (DAR), a leading provider of crypto asset data and research, today announced the availability of newly enhanced crypto Asset Vetting Reports for institutional clients.

Key Points:

NEW YORK, Nov. 18, 2021 /PRNewswire-PRWeb/ -- Digital Asset Research (DAR), a leading provider of crypto asset data and research, today announced the availability of newly enhanced crypto Asset Vetting Reports for institutional clients.
DAR has performed crypto asset vetting since 2017 and its Asset Vetting Reports use a standards-based approach to address key concerns related to public crypto assets, including safety of asset use and custody, health of the asset's ecosystem, decentralization metrics, and more.
"Choosing to onboard or support a crypto asset carries some risk and is challenging for regulated firms," said Doug Schwenk, DAR's CEO.
"Our updated Asset Vetting Reports allow firms to fully evaluate and make an informed decision about individual crypto assets by providing key background information and quantifiable network metrics in an easily consumable format."